

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Sunil Chada *et al.*

Serial No.: 10/017,472

Filed: December 7, 2001

For: METHOD OF TREATMENT INVOLVING  
HUMAN MDA-7

Group Art Unit: 1633

Examiner: Li, Qian Janice

Atty. Dkt. No.: INGN:097US

Confirmation No.: 5209

**CERTIFICATE OF ELECTRONIC TRANSMISSION**  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being  
electronically filed with the United States Patent and  
Trademark Office via FES-Web on the date below:

March 2, 2007  
Date

  
Travis Wohlers

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/INGN:097US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Travis Wohlers  
Reg. No. 57,423  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 2, 2007

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C262	Bocangel <i>et al.</i> , "Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells," <i>Cancer Gene Therapy</i> , 1-11, 2006.
	C263	Chada <i>et al.</i> , "mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biological therapies and radiotherapy: correlation with expression of bcl-2 family members," <i>Cancer Gene Therapy</i> , 1-13, 2005.
	C264	Emdad <i>et al.</i> , "Ionizing Radiation Enhances Adenoviral Vector Expressing mda-7/IL-24-mediated Apoptosis in Human Ovarian Cancer," <i>J. Cell Physiol.</i> , 208:298-306, 2006.
	C265	Inoue <i>et al.</i> , "MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic," <i>Current Gene Therapy</i> , 6:73-91, 2006.
	C266	Kawabe <i>et al.</i> , "Adenovirus-Mediated mda-7 Gene Expression Radiosensitizes Non-Small Cell Lung Cancer Cells via TP53-Independent Mechanisms," <i>Molecular Therapy</i> , 6:637-644, 2002.
	C267	McKenzie <i>et al.</i> , "Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells," <i>Surgery</i> , 136:437-442, 2004.
	C268	Nishikawa <i>et al.</i> , "Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells," <i>Oncogene</i> , 23:7125-7131, 2004.
	C269	Nishikawa <i>et al.</i> , "Adenovirus-Mediated mda-7 (IL24) Gene Therapy Suppresses Angiogenesis and Sensitizes NSCLC Xenograft Tumors to Radiation," <i>Mol. Therapy</i> , 9:818-828, 2004.

25751368.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: INGN:097US	Serial No.: 10/017,472
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Sunil Chada <i>et al.</i>	
		Filing Date: December 7, 2001	Group: 1633
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C270	Su <i>et al.</i> , "Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostrate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2," <i>Oncogene</i> , 25:2339-2348, 2006.

25751368.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)